In seropositive early RA, posthoc analysis of the AVERT [47] and AGREE [48] trials revealed a greater decrease of anti-CCP levels or seroconversion induced by ABA + MTX versus MTX monotherapy, followed by better clinical [49] and radiological outcomes than patients on MTX alone, or patients on either arm which remained ACPA positive [25]. Here, PRTN3 is linked to rheumatoid arthritis.